Development of nicotinic drug therapy for cognitive disorders

European Journal of Pharmacology

Volumn 393, Issue 1-3, 2000, Pages 141-146

  Levin, Edward D ^a   Rezvani, Amir H ^a  

^a B   (United States)

Author keywords

Attention; Learning; Memory; Nicotine

Indexed keywords

DEANOL; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; ISONICOTINE; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NORISONICOTINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ATTENTION; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; CONFERENCE PAPER; HIPPOCAMPUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; WORKING MEMORY;

ADULT; ALZHEIMER DISEASE; ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; LEARNING; MEMORY; NICOTINE; NICOTINIC AGONISTS; RATS; SCHIZOPHRENIA; SMOKING;

EID: 0034732092     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00885-7     Document Type: Conference Paper

References (56)

1. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry. 150:1993;1856-1861.
2. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. 37:1997;153-214.
3. Conners C.K. The Continuous Performance Test (CPT): Use as a diagnostic tool and measure of treatment outcome. Annual Convention of the American Psychological Association, Los Angeles, CA:1994.
4. Conners C.K. The Continuous Performance Test. 1995;Multi-Health Systems, Toronto.
5. Conners C.K., Levin E.D., Sparrow E., Hinton S., Ernhardt D., Meck W.H., Rose J.E., March J. Nicotine and attention in adult ADHD. Psychopharmacol. Bull. 32:1996;67-73.
6. Elrod K., Buccafusco J.J., Jackson W.J. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci. 43:1988;277-287.
7. Felix R., Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience. 81:1997;1009-1017.
8. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry. 38:1995;22-33.
9. Giacobini E., DeSarno P., McIlhany M., Clark B. The cholinergic receptor system in the frontal lobe of Alzheimer's patients. Clementi F., Gotti C., Sher E. Nicotinic Acetylcholine Receptors in the Nervous System. 1988;367-378 Springer-Verlag, Berlin.
10. Grigoryan G., Hodges H., Mitchell S., Sinden J.D., Gray J.A. 6-OHDA lesions of the nucleus accumbens accentuate memory deficits in animals with lesions to the forebrain cholinergic projection system: effects of nicotine administration on learning and memory in the water maze. Neurobiol. Learn. Mem. 65:1996;135-153.
11. Hatsukami D., Fletcher L., Morgan S., Keenan R., Amble P. The effects of varying cigarette deprivation duration on cognitive and performance tasks. J. Sub. Abuse. 1:1989;407-416.
12. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevelance of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
13. Jackson W.J., Buccafusco J.J. Nicotinic enhancement of delayed matching by monkeys is specific to the most difficult problems. Soc. Neurosci. Abs. 15:1989;731.
14. Jones G.M.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology. 108:1992;485-494.
15. Kellar K.J., Wonnacott S. Nicotinic cholinergic receptors in Alzheimer's disease. Wonnacott S., Russell M.A.H., Stolerman I.P. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioral Aspects. 1990;341-373 Oxford Univ. Press, Oxford.
16. Kim J., Levin E. Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: Effects on spatial working memory in rats. Brain Res. 725:1996;231-240.
17. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22:1996;431-445.
18. Levin E., Bettegowda C., Blosser J., Gordon J. AR-R 17779, an α7 nicotinic agonist improves learning and memory in rats. Behav. Pharmacol. 1999a;. in press.
19. Levin E., Conners C., Silva D., Hinton S., Meck W., March J., Rose J. Transdermal nicotine effects on attention. Psychopharmacology. 140:1998a;135-141.
20. Levin E., Kaplan S., Boardman A. Acute nicotine interactions with nicotinic and muscarinic antagonists: Working and reference memory effects in the 16-arm radial maze. Behav. Pharmacol. 8:1997;236-242.
21. Levin E., Kim P., Meray R. Chronic nicotine effects on working and reference memory in the 16-arm radial maze: Interactions with D1 agonist and antagonist drugs. Psychopharmacology. 127:1996;25-30.
22. Levin E., Wilson W., Rose J., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996b;429-436.
23. Levin E.D., Bettegowda C., Weaver T., Christopher N.C. Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. 61:1998;335-340.
24. Levin E.D., Bradley A., Sigurani N. Hippocampal nicotinic receptors and memory function in rats. Society for Research on Nicotine and Tobacco, San Diego:1999.
25. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Persistence of chronic nicotine-induced cognitive facilitation. Behav. Neural Biol. 58:1992;152-158.
26. Levin E.D., Briggs S.J., Christopher N.C., Rose J.E. Chronic nicotinic stimulation and blockade effects on working memory. Behav. Pharmacol. 4:1993;179-182.
27. Levin E.D., Castonguay M., Ellison G.D. Effects of the nicotinic receptor blocker, mecamylamine, on radial arm maze performance in rats. Behav. Neural Biol. 48:1987;206-212.
28. Levin E.D., Christopher N.C., Briggs S.J., Rose J.E. Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Cognit. Brain Res. 1:1993;137-143.
29. Levin E.D., Christopher N.C., Weaver T., Moore J., Brucato F. Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. Cognit. Brain Res. 7:1999;405-410.
30. Levin E.D., Conners C.K., Sparrow E., Hinton S., Meck W., Rose J.E., Ernhardt D., March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology. 123:1996;55-63.
31. Levin E.D., Damaj M.I., Glassco W., May E.L., Martin B.R. Bridged nicotine, isonicotine and norisonicotine effects on working memory performance of rats in the radial-arm maze. Drug Dev. Res. 46:1999;106-111.
32. Levin E.D., Lee C., Rose J.E., Reyes A., Ellison G., Jarvik M., Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav. Neural Biol. 53:1990;269-276.
33. 2 agonist, LY 171555. Pharmacol. Biochem. Behav. 33:1989;919-922.
34. Levin E.D., Rose J.E. Anticholinergic sensitivity following chronic nicotine administration as measured by radial-arm maze performance in rats. Behav. Pharmacol. 1:1990;511-520.
35. Levin E.D., Rose J.E. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Res. Bull. 27:1991;125-128.
36. Levin E.D., Rose J.E., Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. 51:1995;369-373.
37. Levin E.D., Rose J.E., McGurk S.R., Butcher L.L. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav. Neural Biol. 53:1990;103-112.
38. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology. 138:1998;217-230.
39. Levin E.D., Toll K., Chang G., Christopher N.C., Briggs S.J. Epibatidine, a potent nicotinic agonist: effects on learning and memory in the radial-arm maze. Medicinal Chem. Res. 6:1996;543-554.
40. 2 dopaminergic drugs. Psychopharmacology. 99:1989;371-373.
41. Newhouse P.A., Potter A., Levin E.D. Nicotinic systems and Alzheimer's disease: Implications for therapeutics. Drugs Aging. 11:1997;206-228.
42. Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A., Murphy D.L. Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology. 95:1988;171-175.
43. Nordberg A., Adem A., Hardy J., Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 88:1988;317-321.
44. Parks R., Becker R., Rippey R., Gilbert D., Matthews J., Kabatay E., Young C., Vohs C., Danz V., Keim P., Collins G., Zigler S., Urycki P. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: A pilot double blind transdermal nicotine positron emission tomography study. Neuropsychol. Rev. 6:1996;61-79.
45. Perry E.K., Perry R.H., Smith C.J., Dick D.J., Candy J.M., Edwardson J.A., Fairbairn A., Blessed G. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J. Neurol., Neurosurg. Psychiatry. 50:1987;806-809.
46. Quiron R., Martel J.C., Robitaille Y., Etienne P., Wood P., Nair N.P.V., Gauthier S. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer's type. Can. J. Neurol. Sci. 13:1986;503-510.
47. Rinne J.O., Myllykylä T., Lönnberg P., Marjamäki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 547:1991;167-170.
48. Sahakian B.J., Jones G.M.M. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. Adlkofer F., Thruau K. Effects of Nicotine on Biological Systems. 1991;230-623 Birkhauser Verlag, Basel.
49. Schroder H., Giacobini E., Wevers A., Birtsch A., Schutz U. Nicotinic receptors in Alzheimer's disease. Domino E.F. Brain Imaging of Nicotine and Tobacco Smoking. 1995;73-93 Npp Books, PO Box 1491, Ann Arbor, MI 48106.
50. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Changes in nicotinic and muscarinic receptors in Alzheimer-type dementia. J. Neurochem. 46:1986;288-293.
51. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease. J. Neurosci. Res. 27:1990;349-359.
52. Warburton D., Mancuso G. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology. 135:1998;305-310.
53. Warburton D.M., Arnall C. Improvements in performance without nicotine withdrawal. Psychopharmacology. 115:1994;539-542.
54. White H., Levin E.D. Chronic four week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology. 143:1999;158-165.
55. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., Soriano J., Fine C., Abrams A., Rater M., Polisner D. A cholinergic agonist for attention deficit hyperactivity disorder: A pilot controlled clinical trial of ABT-418 in adults. Am. J. Psychiatry. 1999;. in press.
56. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., Mcfalls E., Kovera C., Mccarten J.R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 51:1995;509-514.